02181 MABPHARM-B
- 0.375
- 0.0000.00%
MABPHARM-B News
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
邁博藥業-B：2023年度報告
Maibo Pharmaceutical-B (02181.HK): net loss of 209 million yuan in 2023
On March 26, Ge Longhui | Maibo Pharmaceutical-B (02181.HK) announced that for the year ended December 31, 2023, the Group's revenue increased 55.9% year-on-year to RMB 87.161 million, mainly due to a sharp increase in drug sales revenue during the reporting period compared to last year. Losses attributable to company owners were approximately RMB 209 million, while losses attributable to company owners during the same period last year were approximately RMB 211 million, with a basic loss of RMB 0.05 per share.
Maibo Pharmaceutical-B (02181) announced 2023 results, operating revenue of about 87.161 million yuan, a year-on-year increase of 55.9%
Maibo Pharmaceutical-B (02181) announced its 2023 results, with revenue of about 87.161 million yuan, a year-on-year increase...
MABPHARM-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Maibo Pharmaceutical-B (02181.HK) will hold a board meeting on March 26 to approve the annual results
Gelonghui March 13 | Maibo Pharmaceutical-B (02181.HK) issued an announcement. The board of directors of the company will hold a board meeting on March 26, 2024 to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended December 31, 2023.
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%
Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.
Intraday Overview | The Tech Index fell more than 2%, Apple concept stocks and pharmaceutical stocks had the highest declines, and Shunyu Optical Technology fell more than 8%
Technet stocks collectively weakened, with Xiaomi falling nearly 4%, Meituan falling nearly 3%, and Kuaishou falling more than 2%; domestic housing stocks continued to decline, with Country Garden falling more than 3%; Longhu Group, Xincheng Development, and Sunac China falling nearly 2%; auto stocks were weak, with Zero Sports Auto and NIO falling more than 5%, and Xiaopeng Motors falling more than 4%.
Innovative drugs, the standard-bearer of the Hong Kong stock market
However, the protagonist leading the rebound of A/H shares in this round is innovative pharmaceuticals+consumer electronics. Judging from the past half month, consumer electronics has performed better in A-shares, while innovative drugs have performed more fiercely in Hong Kong stocks.
Intraday quick overview | The three major indices rushed higher and fell, and the index rose slightly; pharmaceutical stocks and domestic housing stocks had the highest gains, Pharmaceuticals Biotech rose more than 5%, and Country Garden rose more than 4%
Most of the Internet of Technology stocks rose, Kuaishou and Tencent rose nearly 2%; most auto stocks fell; Xiaopeng Motor fell by more than 4%, and Zero Sports fell by more than 3%.
Can we expect a large-scale market? Pharmaceutical funds have rebounded across the board. What I'm most concerned about is actually...
What pharmaceutical fund managers are most worried about now is whether non-pharmaceutical funds and top players will think about it again in the midst of a ferocious pharmaceutical backlash.
The Hong Kong Stock Exchange Index fell nearly 6% in the third quarter, but public funds bucked the trend and increased their positions in this sector
① What was the overall position of public funds in the third quarter? ② What do you think of the Hong Kong stock market in the future?
Opinion | Public investment in Hong Kong stocks in the third quarter: bucked the trend and increased positions, and biomedical holdings increased significantly
Overall, Hong Kong stocks weakened in the third quarter. In particular, after August, the trend declined. The index once hit a new low during the year, and there was also a clear outflow of foreign capital. However, southbound capital continued the buying trend, in stark contrast to the continued weakness of northbound capital.
Intraday Quick Facts | Hong Kong stocks have been rising in recent days! The Science and Technology Index rose by nearly 2%, while science and technology, automotive, and pharmaceutical stocks collectively rose sharply, Pharmaceuticals surged by nearly 7%
The Hang Seng Index rose 1.4%, and the Hang Seng Technology Index rose 1.75%; Science and Technology Network stocks collectively strengthened, with Meituan and Bilibili rising more than 4%, JD, Ali, and Baidu rising nearly 2%, and Tencent and Xiaomi rising more than 1%; most auto stocks rose nearly 6%, Ideal Auto rose more than 3%, and BYD and Xiaopeng Motors rose more than 2%.
Intraday quick overview | Hong Kong stocks weakened again, with the Codex falling nearly 2%; Science and Technology Network stocks and pharmaceutical stocks had the highest declines, and COSCO Haineng rose nearly 5% against the market
The three major indices weakened once again. As of press release, the Hang Seng Index fell 1.12% and the Codex fell 1.66%; Science and Technology Network stocks generally fell, Kuaishou fell nearly 4%, Meituan and Bilibili fell about 3%, NetEase, Tencent, and Ali fell about 2%, Baidu and Xiaomi fell more than 1%; pharmaceutical stocks weakened, Lepu Biotech fell nearly 11%, and BeiGene fell nearly 6%.
MABPHARM-B: 2023 Interim Report
Maibo Pharmaceutical-B (02181) released interim results. Losses attributable to shareholders of 99.999 million yuan decreased by 14.4% year-on-year
Maibo Pharmaceutical-B (02181) announced its interim results for the 6 months ended June 30, 2023. The group achieved...
Analysis
Price Target
No Data
